- Trials with a EudraCT protocol (3)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3 result(s) found for: Rat Park.
Displaying page 1 of 1.
| EudraCT Number: 2010-021621-12 | Sponsor Protocol Number: NAI114373 | Start Date*: 2010-12-01 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: NAI114373: A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of ... | |||||||||||||
| Medical condition: hospitalised adults and adolescents with influenza | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) DE (Completed) FR (Completed) GB (Completed) HU (Completed) NL (Completed) CZ (Completed) NO (Completed) DK (Completed) GR (Completed) BE (Completed) PL (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-022951-49 | Sponsor Protocol Number: 20100007 | Start Date*: 2011-06-06 | |||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||
| Full Title: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefracto... | |||||||||||||
| Medical condition: Chemorefractory, Wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS), Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) EE (Completed) LV (Completed) LT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-024540-15 | Sponsor Protocol Number: C38072/3085 | Start Date*: 2011-07-20 | |||||||||||
| Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
| Full Title: An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Stu... | |||||||||||||
| Medical condition: Treatment for patients with eosinophilic asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) SE (Completed) CZ (Completed) GR (Completed) HU (Completed) NL (Completed) DK (Prematurely Ended) PL (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.